Information

Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

You search for a phrase ""Biosimilar Pharmaceuticals"" according to the criterion: Subject Terms


Title:
Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
Authors:
Nguyen AQ; Department of Health Policy and Economics, Hanoi University of Public Health, Hanoi, Vietnam.
Tran OTM; Vietnam Strategy and Planning Institute, Hanoi, Vietnam.
Nguyen PK; Vietnam Strategy and Planning Institute, Hanoi, Vietnam.
Nguyen HT; Department of Health Policy and Economics, Hanoi University of Public Health, Hanoi, Vietnam.
Show more
Source:
PloS one [PLoS One] 2024 Mar 15; Vol. 19 (3), pp. e0300474. Date of Electronic Publication: 2024 Mar 15 (Print Publication: 2024).
Publication Type:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Biosimilar Pharmaceuticals*/therapeutic use
Humans ; Female ; Trastuzumab/therapeutic use ; Cost-Benefit Analysis ; Vietnam ; Receptor, ErbB-2 ; Antibodies, Monoclonal, Humanized/therapeutic use ; Chemotherapy, Adjuvant ; Quality-Adjusted Life Years
Academic Journal
Title:
Comparative physicochemical and structural characterisation studies establish high biosimilarity between BGL-ASP and reference insulin aspart.
Authors:
Ghade NS; BioGenomics Limited, Thane, Maharashtra, 400610, India. .
Thappa DK; BioGenomics Limited, Thane, Maharashtra, 400610, India.
Lona J; BioGenomics Limited, Thane, Maharashtra, 400610, India.
Krishnan AR; BioGenomics Limited, Thane, Maharashtra, 400610, India.
Sonar SM; BioGenomics Limited, Thane, Maharashtra, 400610, India.
Show more
Source:
Scientific reports [Sci Rep] 2024 Feb 20; Vol. 14 (1), pp. 4224. Date of Electronic Publication: 2024 Feb 20.
Publication Type:
Comparative Study; Journal Article
MeSH Terms:
Biosimilar Pharmaceuticals*/therapeutic use
Diabetes Mellitus, Type 2*/drug therapy
Humans ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; India ; Insulin/therapeutic use ; Insulin Aspart/therapeutic use ; United States
Academic Journal
Title:
Long-term outcomes with HLX01 (HanliKang ), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
Authors:
Qin Y; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, 100021, Beijing, China.
Song Y; Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wang D; Department of Oncology, Army Characteristic Medical Center, Chongqing, China.
Bai O; Department of Hematology, Cancer Center, the First Hospital of Jilin University, Changchun, China.
Feng J; Department of Oncology, Jiangsu Cancer Hospital, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing, China.
Sun X; Department of Medical Oncology, the Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Qiu L; Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin, China.
Yang J; Department of Hematology, Changhai Hospital, Naval Medical University, Shanghai, China.
Yang Y; Department of Lymphoma & Head and Neck Tumors, Fujian Medical University Cancer Hospital, Fuzhou, China.
Wang Z; Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Hu J; Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Wang H; Department of Medical Oncology, Tianjin Union Medical Centre of Nankai University, Tianin, China.
Su H; Department of Lymphoma, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Jin Z; Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Qian W; Department of Hematology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Jin C; Department of Oncology, Guangzhou Medical University, Guangzhou, China.
Zhang M; Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yu D; Department of Oncology Medicine, Hubei Cancer Hospital, Wuhan, China.
Liu L; Department of Hematology, the Second Affiliated Hospital of Air Force Medical University (Tangdu Hospital), Xian, China.
Chen G; Department of Hematology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Li Y; Hematology and Oncology Department, the Second Hospital of Jilin University, Changchun, China.
Sun T; Department of Breast Medicine, Liaoning Cancer Hospital, Shenyang, China.
Jin J; Department of Hematology, the First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, China.
Bao H; Department of Lymphology and Hematology, Jilin Provincial Cancer Hospital, Changchun, China.
Du X; Department of Hematology, Guangdong Provincial People's Hospital, Guangzhou, China.
Zhou H; Department of Lymphoma & Hematology, Hunan Cancer Hospital, Changsha, China.
Fu G; Department of Hematology, Xiangya Hospital, Central South University, Changsha, China.
Shi Y; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, 100021, Beijing, China. .
Show more
Source:
BMC cancer [BMC Cancer] 2024 Jan 24; Vol. 24 (1), pp. 124. Date of Electronic Publication: 2024 Jan 24.
Publication Type:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Biosimilar Pharmaceuticals*/adverse effects
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Humans ; Rituximab/adverse effects ; Follow-Up Studies ; Cyclophosphamide/adverse effects ; Doxorubicin ; Prednisone/adverse effects
Academic Journal
Title:
Naphthoquinone Derivatives from Angustimassarina populi CF-097565 Display Anti-Tumour Activity in 3D Cultures of Breast Cancer Cells.
Authors:
Mackenzie TA; Fundación MEDINA, Av. Conocimiento 34, Health Sciences Technology Park, 18016 Granada, Spain.
Reyes F; Fundación MEDINA, Av. Conocimiento 34, Health Sciences Technology Park, 18016 Granada, Spain.
Martínez M; Fundación MEDINA, Av. Conocimiento 34, Health Sciences Technology Park, 18016 Granada, Spain.
González-Menéndez V; Fundación MEDINA, Av. Conocimiento 34, Health Sciences Technology Park, 18016 Granada, Spain.
Sánchez I; Fundación MEDINA, Av. Conocimiento 34, Health Sciences Technology Park, 18016 Granada, Spain.
Genilloud O; Fundación MEDINA, Av. Conocimiento 34, Health Sciences Technology Park, 18016 Granada, Spain.
Tormo JR; Fundación MEDINA, Av. Conocimiento 34, Health Sciences Technology Park, 18016 Granada, Spain.
Ramos MC; Fundación MEDINA, Av. Conocimiento 34, Health Sciences Technology Park, 18016 Granada, Spain.
Show more
Source:
Molecules (Basel, Switzerland) [Molecules] 2024 Jan 15; Vol. 29 (2). Date of Electronic Publication: 2024 Jan 15.
Publication Type:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Ascomycota*
Biosimilar Pharmaceuticals*
Female ; Humans ; Biological Assay
SCR Organism:
Angustimassarina populi
Academic Journal
Title:
Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product.
Authors:
Cantin G; Amgen Inc., Thousand Oaks, CA, USA. .
Liu Q; Amgen Inc., Thousand Oaks, CA, USA.
Shah B; Amgen Inc., Thousand Oaks, CA, USA.
Kuhns S; Amgen Inc., Thousand Oaks, CA, USA.
Wikström M; Amgen Inc., Thousand Oaks, CA, USA.
Cao S; Amgen Inc., Thousand Oaks, CA, USA.
Liu J; Amgen Inc., Thousand Oaks, CA, USA.
Show more
Source:
Drugs in R&D [Drugs R D] 2023 Dec; Vol. 23 (4), pp. 421-438. Date of Electronic Publication: 2023 Oct 13.
Publication Type:
Journal Article
MeSH Terms:
Biosimilar Pharmaceuticals*/pharmacology
Biosimilar Pharmaceuticals*/chemistry
Arthritis, Psoriatic*
Humans ; United States ; Ustekinumab/pharmacology ; Ustekinumab/therapeutic use
Academic Journal
Title:
Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab.
Authors:
Miguel-Lillo B; Medical Department, mAbxience Research S.L., Madrid, Spain.
Sánchez-Vidaurre S; Medical Department, mAbxience Research S.L., Madrid, Spain.
Pérez Díaz L; Medical Department, mAbxience Research S.L., Madrid, Spain.
Paravisini A; Medical Department, mAbxience Research S.L., Madrid, Spain.
Show more
Source:
Pharmacology research & perspectives [Pharmacol Res Perspect] 2023 Dec; Vol. 11 (6), pp. e01139.
Publication Type:
Journal Article; Meta-Analysis
MeSH Terms:
Biosimilar Pharmaceuticals*/adverse effects
Biosimilar Pharmaceuticals*/pharmacokinetics
Humans ; Antibodies, Monoclonal ; Area Under Curve ; Bevacizumab/adverse effects ; Bevacizumab/pharmacokinetics ; Therapeutic Equivalency
Academic Journal
Title:
Knowledge and attitudes of German and Swiss community pharmacists towards biologicals and biosimilars - a prospective survey before and after the COVID-19 pandemic.
Authors:
Messner K; Pharmaceutical Care Research Group, University of Basel, Basel, Switzerland. .
Eickhoff C; Department of Medicine, ABDA - Federal Union of German Associations of Pharmacists, Berlin, Germany.
Schulz M; Department of Medicine, ABDA - Federal Union of German Associations of Pharmacists, Berlin, Germany.; Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.
Allemann SS; Pharmaceutical Care Research Group, University of Basel, Basel, Switzerland.
Arnet I; Pharmaceutical Care Research Group, University of Basel, Basel, Switzerland.
Show more
Source:
BMC health services research [BMC Health Serv Res] 2023 Dec 18; Vol. 23 (1), pp. 1432. Date of Electronic Publication: 2023 Dec 18.
Publication Type:
Journal Article
MeSH Terms:
Biosimilar Pharmaceuticals*/therapeutic use
COVID-19*/epidemiology
Humans ; Pharmacists ; Pandemics ; Prospective Studies ; Switzerland/epidemiology
Academic Journal
Title:
Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.
Authors:
Ruda RC; Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Kelly KA; Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Feldman SR; Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.; Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA.; Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA.; Department of Dermatology, University of Southern Denmark, Odense, Denmark.
Show more
Source:
The Journal of dermatological treatment [J Dermatolog Treat] 2023 Dec; Vol. 34 (1), pp. 2140569.
Publication Type:
Journal Article; Review
MeSH Terms:
Biosimilar Pharmaceuticals*/therapeutic use
Psoriasis*/drug therapy
Humans ; Infliximab/therapeutic use ; Etanercept/therapeutic use ; Adalimumab/therapeutic use ; Biological Factors/therapeutic use ; Tumor Necrosis Factor Inhibitors/therapeutic use
Academic Journal
Title:
Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study.
Authors:
Mageau A; Centre de référence des cytopénies auto-immunes de l'adulte, Service de Médecine Interne, Hôpital Henri Mondor, APHP, UPEC, Créteil, France.
Bonnotte B; Service de Médecine Interne et d'Immunologie Clinique, CHU Dijon-Bourgogne, Dijon, France.
Ebbo M; Département de Médecine Interne, Aix Marseille Univ, APHM, Hôpital de la Timone, Marseille, France.
Dossier A; Service de Médecine Interne, Hôpital Bichat-Claude Bernard, APHP, Université de Paris, Paris, France.
Galicier L; Service d'Immunopathologie Clinique, Hôpital Saint-Louis, APHP, Université de Paris, Paris, France.
Souchaud-Debouverie O; Service de Médecine Interne, Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
Orvain C; Service des Maladies du Sang, Centre Hospitalier Universitaire (CHU) d'Angers, Angers, France.
Gerfaud-Valentin M; Service de Médecine Interne, Hôpital de la Croix-Rousse, HCL, Lyon, France.
Gobert D; Service de Médecine Interne, Hôpital Saint-Antoine, APHP, Université de Paris, Paris, France.
Riviere E; Service de médecine interne CHU Bordeaux, Université de Bordeaux, Bordeaux, France.
Audia S; Service de Médecine Interne et d'Immunologie Clinique, CHU Dijon-Bourgogne, Dijon, France.
Mahevas M; Centre de référence des cytopénies auto-immunes de l'adulte, Service de Médecine Interne, Hôpital Henri Mondor, APHP, UPEC, Créteil, France.
Michel M; Centre de référence des cytopénies auto-immunes de l'adulte, Service de Médecine Interne, Hôpital Henri Mondor, APHP, UPEC, Créteil, France.
Viallard JF; Service de médecine interne CHU Bordeaux, Université de Bordeaux, Bordeaux, France.
Godeau B; Centre de référence des cytopénies auto-immunes de l'adulte, Service de Médecine Interne, Hôpital Henri Mondor, APHP, UPEC, Créteil, France.
Show more
Source:
Platelets [Platelets] 2023 Dec; Vol. 34 (1), pp. 2200848.
Publication Type:
Observational Study; Journal Article
MeSH Terms:
Biosimilar Pharmaceuticals*/therapeutic use
Purpura, Thrombocytopenic, Idiopathic*/drug therapy
Thrombocytopenia*/drug therapy
Adult ; Humans ; Rituximab/therapeutic use
Academic Journal
Title:
Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience.
Authors:
Maurelli M; Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Girolomoni G; Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Gisondi P; Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Show more
Source:
The Journal of dermatological treatment [J Dermatolog Treat] 2023 Dec; Vol. 34 (1), pp. 2218504.
Publication Type:
Journal Article
MeSH Terms:
Biosimilar Pharmaceuticals*/therapeutic use
Psoriasis*/drug therapy
Adult ; Humans ; Methotrexate/therapeutic use ; Adalimumab ; Treatment Outcome
Academic Journal
Title:
In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
Authors:
Tak M; Quality Evaluation Team, Samsung Bioepis Co., Ltd., 76, Songdogyoyuk-ro, Yeonsu-gu, Incheon, 21987, Republic of Korea.
Jeong H; Quality Evaluation Team, Samsung Bioepis Co., Ltd., 76, Songdogyoyuk-ro, Yeonsu-gu, Incheon, 21987, Republic of Korea.
Yun J; Quality Evaluation Team, Samsung Bioepis Co., Ltd., 76, Songdogyoyuk-ro, Yeonsu-gu, Incheon, 21987, Republic of Korea.
Kim J; Quality Evaluation Team, Samsung Bioepis Co., Ltd., 76, Songdogyoyuk-ro, Yeonsu-gu, Incheon, 21987, Republic of Korea.
Kim S; Quality Evaluation Team, Samsung Bioepis Co., Ltd., 76, Songdogyoyuk-ro, Yeonsu-gu, Incheon, 21987, Republic of Korea.
Lee Y; Quality Evaluation Team, Samsung Bioepis Co., Ltd., 76, Songdogyoyuk-ro, Yeonsu-gu, Incheon, 21987, Republic of Korea.
Park SJ; Quality Evaluation Team, Samsung Bioepis Co., Ltd., 76, Songdogyoyuk-ro, Yeonsu-gu, Incheon, 21987, Republic of Korea. .
Show more
Source:
Drugs in R&D [Drugs R D] 2023 Dec; Vol. 23 (4), pp. 363-375. Date of Electronic Publication: 2023 Aug 22.
Publication Type:
Journal Article
MeSH Terms:
Saline Solution*
Biosimilar Pharmaceuticals*/chemistry
Humans ; Sodium Chloride ; Glucose ; Drug Stability ; Drug Packaging ; Chromatography, High Pressure Liquid
Academic Journal
Title:
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab.
Authors:
Jiang Y; Coherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
Arora T; Coherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.; Bristol Myers Squibb Inc., Redwood City, CA, USA.
Klakamp S; Coherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
Davis J; Coherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
Chandrasekher YA; Coherus BioSciences Inc., Redwood City, CA, USA.
Young G; Coherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
Du Y; Coherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
Yu B; Coherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
Miller KJ; Coherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA. .
Show more
Source:
Drugs in R&D [Drugs R D] 2023 Dec; Vol. 23 (4), pp. 377-395. Date of Electronic Publication: 2023 Aug 26.
Publication Type:
Journal Article
MeSH Terms:
Biosimilar Pharmaceuticals*/chemistry
Humans ; Adalimumab/chemistry ; Adalimumab/pharmacology
Academic Journal
Title:
Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis.
Authors:
Li C; Department of Pharmacy, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China.
Sunhe Y; School of Pharmacy, Xi'an Medical College, Xi'an, PR China.
Zhou H; Department of Pharmacy, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China.
Dong W; Department of Pharmacy, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China.
Show more
Source:
The Journal of dermatological treatment [J Dermatolog Treat] 2023 Dec; Vol. 34 (1), pp. 2249145.
Publication Type:
Meta-Analysis; Journal Article; Review
MeSH Terms:
Biosimilar Pharmaceuticals*/adverse effects
Psoriasis*/drug therapy
Humans ; Adalimumab/adverse effects ; China ; Databases, Factual
Academic Journal
Title:
Multiple COVID reinfections in a vaccinated psoriatic patient receiving adalimumab.
Authors:
Zargari O; Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Azimi SZ; Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
Show more
Source:
The Journal of dermatological treatment [J Dermatolog Treat] 2023 Dec; Vol. 34 (1), pp. 2149237. Date of Electronic Publication: 2022 Nov 22.
Publication Type:
Case Reports; Journal Article
MeSH Terms:
Adalimumab*/adverse effects
Biosimilar Pharmaceuticals*/therapeutic use
COVID-19*/prevention & control
COVID-19 Vaccines*/adverse effects
Psoriasis*/drug therapy
Adult ; Humans ; Male ; Antibodies, Viral ; Reinfection ; SARS-CoV-2 ; Tumor Necrosis Factor Inhibitors ; Vaccination
Academic Journal
Title:
Imbalanced machine learning classification models for removal biosimilar drugs and increased activity in patients with rheumatic diseases.
Authors:
Castro Corredor D; Rheumatology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.
Calvo Pascual LÁ; Department of Quantitative Methods. ICADE, Universidad Pontificia de Comillas Madrid, Madrid, Spain.
Show more
Source:
PloS one [PLoS One] 2023 Nov 30; Vol. 18 (11), pp. e0291891. Date of Electronic Publication: 2023 Nov 30 (Print Publication: 2023).
Publication Type:
Journal Article; Observational Study
MeSH Terms:
Biosimilar Pharmaceuticals*/pharmacology
Rheumatic Diseases*/drug therapy
Humans ; Machine Learning ; Retrospective Studies
Academic Journal
Title:
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
Authors:
Chen L; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangdong, Guangzhou, China.
Rangel JDG; Clinical Medical Research S.C, Veracruz, México.
Cil T; Health and Science University, Adana City Education and Research Hospital, Adana, Turkey.
Li X; The First Affiliated Hospital of Zhengzhou University, Henan, Zhengzhou, China.
Cicin I; Trakya University Medical Faculty, Edirne, Turkey.
Shen Y; The First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
Liu Z; Jiangxi Cancer Hospital, Jiangxi, Nanchang, China.
Ozyilkan O; Baskent University Adana Application and Research Center, Adana, Turkey.
Igor B; CNE 'City Clinical Hospital No4', Dnipro, Ukraine.
Chen J; Tianjin Medical University General Hospital, Tianjin, China.
Oleksandr K; Podilskyi Regional Oncological Center, Vinnytsia, Ukraine.
Chen Z; The Second Hospital of Anhui Medical University, Anhui, Hefei, China.
Zhang H; Tangdu Hospital, Fourth Military Medical University, Shanxi, Xi'an, China.
Fu Z; Bio-Thera Solutions, Ltd., Guangdong, Guangzhou, China.
Dong Q; Bio-Thera Solutions, Ltd., Guangdong, Guangzhou, China.
Song S; Bio-Thera Solutions, Ltd., Guangdong, Guangzhou, China.
Yu JC; Bio-Thera Solutions, Ltd., Guangdong, Guangzhou, China.
Zhang L; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangdong, Guangzhou, China.
Show more
Source:
Cancer medicine [Cancer Med] 2023 Nov; Vol. 12 (22), pp. 20847-20863. Date of Electronic Publication: 2023 Nov 07.
Publication Type:
Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Biosimilar Pharmaceuticals*/adverse effects
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Humans ; Antineoplastic Combined Chemotherapy Protocols ; Bevacizumab/adverse effects ; Carboplatin/therapeutic use ; Double-Blind Method ; Paclitaxel/therapeutic use
Academic Journal
Title:
Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial.
Authors:
Dziri C; Tunis Medical School, Tunis El Manar University, Tunis, Tunisia.; Honoris Medical Simulation Center, Tunis Montplaisir, Tunisia.
Ben Hmida W; Department B of General Surgery, Charles Nicolle's Hospital, Tunis El Manar University, Tunis, Tunisia.
Dougaz W; Department B of General Surgery, Charles Nicolle's Hospital, Tunis El Manar University, Tunis, Tunisia.
Khalfallah M; Department B of General Surgery, Charles Nicolle's Hospital, Tunis El Manar University, Tunis, Tunisia.
Samaali I; Department B of General Surgery, Charles Nicolle's Hospital, Tunis El Manar University, Tunis, Tunisia.
Jerraya H; Department B of General Surgery, Charles Nicolle's Hospital, Tunis El Manar University, Tunis, Tunisia.
Bouasker I; Department B of General Surgery, Charles Nicolle's Hospital, Tunis El Manar University, Tunis, Tunisia.
Nouira R; Department B of General Surgery, Charles Nicolle's Hospital, Tunis El Manar University, Tunis, Tunisia.
Show more
Source:
PloS one [PLoS One] 2023 Nov 01; Vol. 18 (11), pp. e0293269. Date of Electronic Publication: 2023 Nov 01 (Print Publication: 2023).
Publication Type:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Venous Thromboembolism*/etiology
Venous Thromboembolism*/prevention & control
Venous Thromboembolism*/drug therapy
Biosimilar Pharmaceuticals*/adverse effects
Venous Thrombosis*/prevention & control
Thrombosis*/drug therapy
Gastrointestinal Neoplasms*/drug therapy
Humans ; Enoxaparin/adverse effects ; Anticoagulants/therapeutic use ; Postoperative Complications/prevention & control ; Postoperative Complications/drug therapy
Academic Journal
Title:
Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis.
Authors:
Aungsumart S; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.; Neuroimmunology Unit, Department of Neurology, Neurological Institute of Thailand, Bangkok, Thailand.
Turongkaravee S; Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Youngkong S; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.; Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Apiwattanakul M; Neuroimmunology Unit, Department of Neurology, Neurological Institute of Thailand, Bangkok, Thailand.
Thakkinstian A; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand.; Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Chaikledkaew U; Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand. .; Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand. .
Show more
Source:
BMC health services research [BMC Health Serv Res] 2023 Oct 13; Vol. 23 (1), pp. 1096. Date of Electronic Publication: 2023 Oct 13.
Publication Type:
Journal Article
MeSH Terms:
Multiple Sclerosis, Relapsing-Remitting*/drug therapy
Multiple Sclerosis*/drug therapy
Biosimilar Pharmaceuticals*/therapeutic use
Humans ; Rituximab/therapeutic use ; Cost-Benefit Analysis ; Thailand ; Quality of Life ; Quality-Adjusted Life Years ; Markov Chains
Academic Journal
Title:
Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis.
Authors:
Herndon TM; Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Ausin C; Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Brahme NN; Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Schrieber SJ; Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Luo M; Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Andrada FC; Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Kim C; Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Sun W; Division of Biometrics VIII, Office of Biostatistics, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Zhou L; Division of Biometrics VIII, Office of Biostatistics, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Grosser S; Division of Biometrics VIII, Office of Biostatistics, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Yim S; Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Ricci MS; Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
Show more
Source:
PloS one [PLoS One] 2023 Oct 03; Vol. 18 (10), pp. e0292231. Date of Electronic Publication: 2023 Oct 03 (Print Publication: 2023).
Publication Type:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Biosimilar Pharmaceuticals*/adverse effects
Anaphylaxis*/chemically induced
Humans ; Biological Factors ; Research Design ; Antibodies
Academic Journal
Title:
A randomized, double-blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers.
Authors:
Makarenko I; R&D Center, GEROPHARM, Saint Petersburg, Russia.; Federal State Budgetary Educational Institution of Higher Education 'A.I. Evdokimov Moscow State University of Medicine and Dentistry' of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.
Dorotenko A; R&D Center, GEROPHARM, Saint Petersburg, Russia.; Valdman Institute of Pharmacology, Pavlov First St. Petersburg State Medical University, Saint Petersburg, Russia.
Noskov S; Clinical Hospital №3, Yaroslavl, Russia.
Banko V; R&D Center, GEROPHARM, Saint Petersburg, Russia.
Saparova V; R&D Center, GEROPHARM, Saint Petersburg, Russia.; Federal State Budgetary Educational Institution of Higher Education 'A.I. Evdokimov Moscow State University of Medicine and Dentistry' of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.
Khokhlov A; Federal State Budgetary Educational Institution of Higher Education, 'Yaroslavl State Medical University' of the Ministry of Health of the Russian Federation, Yaroslavl, Russia.
Zoreeva E; R&D Center, GEROPHARM, Saint Petersburg, Russia.
Nedorubov A; Institute for Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Zinnatulina B; R&D Center, GEROPHARM, Saint Petersburg, Russia.
Gefen M; R&D Center, GEROPHARM, Saint Petersburg, Russia.
Drai R; R&D Center, GEROPHARM, Saint Petersburg, Russia.
Show more
Source:
Pharmacology research & perspectives [Pharmacol Res Perspect] 2023 Oct; Vol. 11 (5), pp. e01125.
Publication Type:
Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article
MeSH Terms:
Biosimilar Pharmaceuticals*/adverse effects
Humans ; Male ; Double-Blind Method ; Recombinant Fusion Proteins/adverse effects ; Healthy Volunteers
Academic Journal

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.